Since the late 1970s, topical β‐adrenergic blockers have been the drugs of choice in
treating ocular hypertension and associated glaucoma. The currently available drugs are …

Topical β-blockers reduce the intraocular pressure (IOP) by blockade of sympathetic nerve
endings in the ciliary epithelium causing a fall in aqueous humour production. Two types of …

Topically administered beta blockers are the preferred medical therapy for glaucoma. These
agents reduce intraocular pressure (IOP), thereby preventing damage to the optic nerve and …

Although topical [beta]-blockers are generally tolerated, they can produce significant
systemic side effects. The systemic side effects of nonselective [beta]-blockers (eg, timolol …

Glaucoma and ocular hypertension are highly prevalent conditions in individuals over the
age of 40 and are commonly seen together in patients with cardiovascular disease. Many of …

Timolol maleate, the first B-adrenergic antagonist available for the treatment of glaucoma
and ocular hypertension, was marketed in 1978 (1). Shortly after its introduction, systemic …

OBJECTIVE: To compare the similarities and differences among the ocular beta-blockers.
Important considerations when comparing these agents are the differences in systemic …

Topical ophthalmic β‐adrenoceptor antagonists (beta‐blockers) are generally recognized as
the treatment of choice in glaucoma management due to favourable efficacy, safety and …

Some beta-adrenoceptor blocking drugs are exciting new ocular hypotensive compounds.
Unlike pilocarpine, the mainstay of glaucoma treatment for the last 100 years, beta-blocking …

Glaucoma, a disease that affects between 1 and 3% of the population above the age of 60,
is most commonly treated by topical beta‐adrenergic blockers. Although effective in lowering …